- Home
- ALT
ALT
Altimmune Inc.
as 11-21-2025 3:40pm EST
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
| Founded: | 1997 | Country: | United States |
| Employees: | 59 | City: | GAITHERSBURG |
| Market Cap: | 501.9M | IPO Year: | N/A |
| Target Price: | $16.33 | AVG Volume (30 days): | 3.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.06 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.90 - $10.88 | Next Earning Date: | 11-06-2025 |
| Revenue: | $20,000 | Revenue Growth: | -61.54% |
| Revenue Growth (this year): | -71.57% | Revenue Growth (next year): | -49.20% |
Latest Altimmune Inc. News
ALT Breaking Stock News: Dive into ALT Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025
TipRanks
14 days ago
Altimmune price target lowered to $14 from $15 at Citizens JMP
GlobeNewswire
15 days ago
Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025
GlobeNewswire
16 days ago
Altimmune Announces Third Quarter 2025 Financial Results and Business Updates
GlobeNewswire
17 days ago
Altimmune to Participate in Two Upcoming Investor Conferences
GlobeNewswire
19 days ago
Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder
24/7 Wall St.
22 days ago
3 Explosive Stocks With High Short Interest
GlobeNewswire
23 days ago
Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025
Compare ALT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALT Altimmune Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.